Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of GEN2 in Refractory Patients With Primary Hepatocellular Carcinoma or Tumors Metastatic to the Liver

NCT04313868 is registered in ClinicalTrials.gov with GenVivo, Inc. as lead sponsor.

NCT NCT04313868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04313868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of GEN2 in Refractory Patients With Primary Hepatocellular Carcinoma or Tumors Metastatic to the Liver
Lead sponsor
GenVivo, Inc.
Phase
Phase 1
Overall status
Completed
Start date
June 13, 2014
Completion date
December 12, 2023
Enrollment
61 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, metastatic cancer